The unexpected effect of PEGylated gold nanoparticles on the primary function of erythrocytes.

Polyethylene glycol-functionalized gold nanoparticles (PEGylated AuNPs) have been widely used as nanocarriers for the delivery of various drugs. However, little attention has been paid to whether the PEGylated AuNPs could affect the primary function of human erythrocytes, which is the main cellular component in the blood. In the current study, we show that both the deformability and oxygen-delivering ability of erythrocytes are decreased when treated with PEGyalted AuNPs of various sizes, which can be attributed to the interaction between PEGylated AuNPs and erythrocyte membranes. It is observed that the PEGylated AuNPs could also induce the aggregation of band-3 and the ATP decrease of erythrocytes. In addition, the PEGylated AuNPs can accelerate the loss of CD47 on erythrocyte membranes, possibly enhancing the senescent process of erythrocytes and the following clearance by SIRPα-expressing leukocytes in bloodstream. The results suggested that PEGylated AuNPs have the potential to affect the primary function of human erythrocytes, which should be considered when using them as drug carriers.

[1]  G. Garratty.  Immune hemolytic anemia associated with drug therapy. , 2010, Blood reviews.

[2]  A. Schechter,et al.  Effects of superoxide anions on red cell deformability and membrane proteins. , 1992, Biorheology.

[3]  Hui Yang,et al.  Effects of gestational age and surface modification on materno-fetal transfer of nanoparticles in murine pregnancy , 2012, Scientific Reports.

[4]  J. Delaunay.  The molecular basis of hereditary red cell membrane disorders. , 2007, Blood reviews.

[5]  David D. Thomas,et al.  Changes in Band 3 oligomeric state precede cell membrane phospholipid loss during blood bank storage of red blood cells , 2009, Transfusion.

[6]  N. Hamasaki,et al.  Red Blood Cell Function and Blood Storage , 2000, Vox Sanguinis.

[7]  S. Grešová,et al.  Hemorheology and circulation. , 2009, Clinical hemorheology and microcirculation.

[8]  P. Buehler,et al.  Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. , 2013, Blood.

[9]  Juan L. Vivero-Escoto,et al.  Mesoporous silica nanoparticles for reducing hemolytic activity towards mammalian red blood cells. , 2009, Small.

[10]  Sabine Neuss,et al.  Gold nanoparticles of diameter 1.4 nm trigger necrosis by oxidative stress and mitochondrial damage. , 2009, Small.

[11]  P. Low,et al.  Role of band 3 in regulating metabolic flux of red blood cells , 2009, Proceedings of the National Academy of Sciences.

[12]  Rajiv K. Saxena,et al.  Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation , 2007, Transfusion.

[13]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[14]  Mostafa A. El-Sayed,et al.  The golden age: gold nanoparticles for biomedicine. , 2012, Chemical Society reviews.

[15]  W. Wilson,et al.  Targeting hypoxia in cancer therapy , 2011, Nature Reviews Cancer.

[16]  Lev Dykman,et al.  Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. , 2011, Chemical Society reviews.

[17]  B. D. de Pauw,et al.  Erythrocyte vesiculation: a self‐protective mechanism? , 2008, British journal of haematology.

[18]  Jin Hong,et al.  Size-dependent tissue kinetics of PEG-coated gold nanoparticles. , 2010, Toxicology and applied pharmacology.

[19]  Hong Wang,et al.  A Method for Purification and Viral Inactivation of Human Placenta Hemoglobin , 2006, Artificial cells, blood substitutes, and immobilization biotechnology.

[20]  James G. White,et al.  Blood-nanoparticle interactions and in vivo biodistribution: impact of surface PEG and ligand properties. , 2012, Molecular pharmaceutics.

[21]  John C Bischof,et al.  Biodistribution of TNF-alpha-coated gold nanoparticles in an in vivo model system. , 2009, Nanomedicine.

[22]  Jun Wang,et al.  Enhancement of lipopolysaccharide-induced nitric oxide and interleukin-6 production by PEGylated gold nanoparticles in RAW264.7 cells. , 2012, Nanoscale.

[23]  D. Kell,et al.  Diagnostic morphology: biophysical indicators for iron-driven inflammatory diseases. , 2014, Integrative biology : quantitative biosciences from nano to macro.

[24]  Baowei Fei,et al.  Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. , 2008, Journal of the American Chemical Society.

[25]  Sokindra Kumar,et al.  Nanoparticles-mediated drug delivery approaches for cancer targeting: a review , 2013, Journal of drug targeting.

[26]  Manuela Semmler-Behnke,et al.  Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. , 2010, Biomaterials.

[27]  I. O. Wallinder,et al.  Hemolytic properties of synthetic nano- and porous silica particles: the effect of surface properties and the protection by the plasma corona. , 2012, Acta biomaterialia.

[28]  H. Dai,et al.  PEG branched polymer for functionalization of nanomaterials with ultralong blood circulation. , 2009, Journal of the American Chemical Society.

[29]  C. Lagenaur,et al.  Role of CD47 as a marker of self on red blood cells. , 2000, Science.

[30]  F. Bakan,et al.  Evaluation of cytotoxic, oxidative stress and genotoxic responses of hydroxyapatite nanoparticles on human blood cells , 2014, Journal of applied toxicology : JAT.

[31]  Deny Hartono,et al.  Autophagy and oxidative stress associated with gold nanoparticles. , 2010, Biomaterials.

[32]  N. Juffermans,et al.  Red Blood Cell Clearance in Inflammation , 2012, Transfusion Medicine and Hemotherapy.

[33]  Mark Stappers,et al.  Changes in band 3 structure as determinants of erythrocyte integrity during storage and survival after transfusion. , 2010, Blood transfusion = Trasfusione del sangue.

[34]  S. Yao,et al.  Nanotoxicity of TiO(2) nanoparticles to erythrocyte in vitro. , 2008, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[35]  G. Mchedlishvili,et al.  Disturbed blood flow structuring as critical factor of hemorheological disorders in microcirculation. , 1998, Clinical hemorheology and microcirculation.

[36]  A. Maček,et al.  Role of erythrocyte deformability in the acute hypoxic pressor response in the pulmonary vasculature. , 1988, Respiration physiology.

[37]  C. Evelo,et al.  Erythrocyte antioxidant defense response against cigarette smoking in humans—the glutathione S‐transferase vulnerability , 2005, Journal of biochemical and molecular toxicology.

[38]  Elodie Boisselier,et al.  Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. , 2009, Chemical Society reviews.

[39]  Erik C. Dreaden,et al.  The Golden Age: Gold Nanoparticles for Biomedicine , 2012 .

[40]  H H Lipowsky,et al.  Capillary recruitment in response to tissue hypoxia and its dependence on red blood cell deformability. , 1999, American journal of physiology. Heart and circulatory physiology.

[41]  C. Sharma,et al.  Blood protein adsorption and compatibility studies of gold nanoparticles , 2011 .

[42]  K. Evelyn,et al.  MICRODETERMINATION OF OXYHEMOGLOBIN, METHEMOGLOBIN, AND SULFHEMOGLOBIN IN A SINGLE SAMPLE OF BLOOD , 1938 .

[43]  S. Urbaniak,et al.  The application of a new quantitative assay for the monitoring of integrin‐associated protein CD47 on red blood cells during storage and comparison with the expression of CD47 and phosphatidylserine with flow cytometry , 2005, Transfusion.